Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

PARP inhibitors for metastatic breast cancer

BGICC 2020

9 - 10 Jan 2020

Published: 29 Jan 2020

Views: 978

Rating:

Save

Prof Banu Arun - MD Anderson Cancer Center, Houston, USA

Prof Banu Arun spoke to ecancer at the BGICC 2020 conference in Cairo, Egypt about PARP inhibitors for metastatic breast cancer.

She highlights some of the recent trials that have been testing PARP inhibitors in this setting.

Prof Arun finalises by suggesting how these trials may develop, particularly looking at combination of platinums.

Related Videos

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors

Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors ( Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain )

Transforming cancer care in India: The Access Cancer Care Initiative

Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran

Transforming cancer care in India: The Access Cancer Care Initiative ( Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran )

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi

Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )

SABCS 2024: Highlights in breast cancer genomic testing

Prof Matteo Lambertini and Prof Virginia Kaklamani

SABCS 2024: Highlights in breast cancer genomic testing ( Prof Matteo Lambertini and Prof Virginia Kaklamani )

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC

Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

More from ecancer